Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
some buying today; what's happening??
Cmon VRDE!!!
This is one thin stock, look at level 2!!
VRDE gonna go , lots of accumulation for the past month
http://stockcharts.com/h-sc/ui?s=VRDE&p=D&b=5&g=0&id=p96726236481
So if this is a shell. The question is it a clean shell and are we up for a R/M.
$0.02? Ouch! that was a pretty f***ed up entry.
As far as DD goes...when I saw this stock I was looking for a pure "price/outstanding shares" play.
Apart from their website (http://www.veridien.com) there is little info about the company, and since they don't file any report they might be a shell company now.
I agree. Have you heard anything about what this outfit is doing? I've been looking for DD and nothing. Got in around .02 and still sitting on alot of shares.
Sure
Dead? Ehm...those junk stocks pop when no one expects it.
Hello! Anyone Home? Thought this dog was dead but........Still hoping this thing would come back, will see??????????
Sure
Veridien Corporation.(VRDE.PK 05.06..09 pps 0.0050) The Group's principal activity is to develop, manufacture, distribute and sell disinfectants, antiseptics and sterilants that are non-toxic, environment friendly and which decompose into harmless naturally occurring organic molecules. VIRAHOL(R), a hard surface disinfectant and VIRAGEL(R), an antiseptic hand gel sanitizer are the major patented products. The products offered by the Group are used by the health care and medical industry and also for consumer and commercial applications.
http://www.nextag.com/veridien/stores-html
LOL.As they stated today May.06.09 VRDE joined PINK community
VRDE huge changes .May.06.2009 From OT to PINK (pps 0.005)...Well.We should see good ride up to 0.04 .
Veridien Moves Forward with Expansion of Sales Representative Network
Last update: 8/14/2008 1:09:01 PMNew Supply Chain Resources Enable Access to Revenue Growth from Private Label Opportunities LARGO, Fla., Aug 14, 2008 (BUSINESS WIRE) --
Veridien Corporation (VRDE) announced today that it has expanded its national medical sales representative network to 28 representatives across the United States and Canada. Paul Dunnigan, VP-Marketing Group said, "Veridien trained 21 medical sales representatives in Q1 and Q2. Veridien has recently added and trained seven more representatives in order to expand sales coverage of all North American markets. Our goal is to have approximately 32 representatives by year end 2008, who will cover all of the United States and Canada. "The role of the medical sales network is to focus on and drive sales in our core business. The representatives, through their extensive client base in the medical arena, have started opening doors into acute care markets, nursing homes and independent surgery centers. Viraguard(R) Infection Control products are now in clinical trials in several American hospitals, as well as nursing homes and two new medical supply distributors. These new developments and the efforts of the 28 sales representatives, are expected to impact revenues in late Q3 and Q4, 2008 and beyond. "In alternative markets, Veridien has continued to grow with pandemic planning programs in Canadian markets. Veridien plans to launch this program in US markets in Q4, 2008. As well, Veridien has established a distributor relationship with FDM Marketing to supply Viraguard(R) Infection Control products to university and college athletic facilities, specifically for the purpose of controlling MRSA outbreaks in athletic environments. "The cost of most Viraguard(R) components have been adversely affected by world oil prices. To offset the slow economy and these rising costs, Veridien has aggressively re-adjusted its supply chain to drive down the cost of manufacturing. This has resulted in new manufacturing resources that are enabling Veridien to bid on large private label contracts in the medical industry and the Sanitation and Janitorial industry. These bid programs are expected to create revenue opportunities commencing in Q4, 2008." "Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 Forward-looking statements in this press release (identifiable by such words as "believes", "projects", "expects", "beginning", "intended", "planned") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements. About Veridien Corporation For more information about Veridien Corporation and its investments in future technology, please visit: and . SOURCE: Veridien Corporation
Veridien Corporation, LargoCheryl Ballou, 727-576-1600 x202
not a pinksheet pos....that's always nice
seems like the news they had a little while back has been pretty darn good
anything going on with this company??
Veridien Reports Sales for the First Nine Months of 2007 of $1,609,191 versus $881,694 for Same Period 2006
Wednesday November 14, 3:19 pm ET
2007 Full Year Sales Projected to Be in Excess of $2,500,000 versus 2006 Sales of $1,850,066
LARGO, Fla.--(BUSINESS WIRE)--Veridien Corporation (OTCBB:VRDE - News) reported Sales for the first nine months of 2007 of $1,609,191 an increase of $727,497 or 83% over 2007 sales for the same period of $881,694. Third Quarter 2007 Sales were $341,560.
ADVERTISEMENT
Veridien is projecting sales for the fiscal year 2007 of over $2,500,000; the highest sales level in the company’s history. This projection is based on: (i) nine month sales as reported to date; (ii) purchase orders in hand of approximately $645,000; (iii) anticipated orders in late/final stages of negotiations; and (iv) recurring orders from existing customers.
Sheldon Fenton, President & CEO of Veridien said, “Over fiscal 2007 we have methodically built on our past successes and by year end we expect that our sales will be in excess of $2,500,000, the highest level in our company’s history.”
Full financial results for the quarter, as filed by Veridien today, are available at www.sec.gov.
Sales for the First 6 Months Increased by 202%
Wednesday August 15, 8:45 am ET
Sales for Second Quarter 2007 Increased by 157% over Second Quarter 2006
http://biz.yahoo.com/bw/070815/20070815005113.html?.v=1
LARGO, Fla.--(BUSINESS WIRE)--Veridien Corporation (OTCBB:VRDE - News) reported Sales for the first six months of 2007 of $1,267,631, an increase of $847,454 or 202% over 2006 sales for the same period of $420,177. Second Quarter 2007 Sales of $680,120, were an increase of 157% over Second Quarter 2006 Sales of $265,054.
The company has just completed the fourth consecutive sales quarter where in each of those quarters, compared to their counterpart in the previous year, sales showed a substantial increase;
Q2/2007 vs Q2/2006: increase of 157%
Q1/2007 vs Q1/2006 : increase of 278%
Q4/2006 vs Q4/2005 : increase of 130%
Q3/2006 vs Q3/2005 : increase of 168%
Sheldon Fenton, President & CEO of Veridien, said, "Our sales team continues to work diligently to increase our sales, focusing on evolving relationships with major strategic partners."
Full financial results for the quarter, as filed by Veridien yesterday, are available at www.sec.gov.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
Forward-looking statements in this press release (identifiable by such words as "believes", "expects", "beginning", "intended", "planned") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.
highest 1Q sales in the company's history em
VRDE Reported Q1/2007 Sales Up 278%
http://biz.yahoo.com/bw/070515/20070515006374.html?.v=1
Veridien Achieves Best Sales Quarter in Corporate History
Friday January 12, 2007
Fourth Quarter 2006 Sales in Excess of $ 930,000, a level which is 220% over Fourth Quarter 2005 Sales
New Antiseptic and Disinfectant Consumer Product Line on Retail Shelves - Initial orders of $ 450,000 Delivered
LARGO, Fla.--(BUSINESS WIRE)--Veridien Corporation (OTCBB:VRDE - News) today announced record Fourth Quarter Sales that are in excess of $ 930,000 (versus Q4/2005 sales of $420,876). These sales surpassed published fourth quarter projections of $ 850,000 as announced in November. Sales activity resulted from the launch of the Viraguard® consumer antiseptic and disinfectant product line in over 434 Canadian retail stores, growing sales to a large multi-national customer and ongoing efforts in the medical/dental markets.
Sheldon Fenton, President & CEO of Veridien said, "Having just completed our fourth quarter, I am pleased to report the highest quarterly sales in the company's history. Our efforts in a number of different facets of our business are beginning to be translated into sustainable sales growth."
Veridien is committed to growing its Viraguard® franchise and is currently working on a number of strategies that are intended to expand its presence in both the retail and institutional sectors of the US and other strategic global markets.
The Viraguard® product line is now available on the shelves of Canadian retailers including Loblaws and Lawtons Drugstores. Initial orders of $ 450,000 have been delivered. Both retailers are carrying the full Viraguard® consumer product line which includes seven (7) SKUs of various configuration and sizes of Hand sprays, Hand wipes, Surface sprays and Surface Wipes.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
Forward-looking statements in this press release (identifiable by such words as "believes", "expects", "beginning", "intended", "planned") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.
About Veridien Corporation
For more information about Veridien Corporation and it investments in future technology, please visit: http://www.veridien.com and http://www.mycosol.com.
Contact:
Veridien Corporation, Largo
Cheryl Ballou, 727-576-1600 x202
----------------------------------------------------
Source: Veridien Corporation
(DEF 14C) Increase auth to 800,000,000 shares 11/29/06
http://www.pinksheets.com/quote/filings.jsp?symbol=VRDE
Breaking above the 200 MDA...Gapper tomorrow
We need to climb over that wall!!!
.045 fake wall getting hit
Nice news today:
VRDE (.037) New Antiseptic and Disinfectant Consumer Product Line on Retail Shelves - Initial Orders of $450,000 Delivered
Business Wire "US Press Releases "
LARGO, Fla.--(BUSINESS WIRE)--
Veridien Corporation (OTCBB:VRDE), through its wholly owned Canadian subsidiary Viraguard Canada Inc., has launched its Viraguard(R) consumer antiseptic and disinfectant product line in over 434 Canadian retail stores. Viraguard(R)'s patented technology platform allows it to deliver effective levels of disinfecting power making this a unique product line for consumers looking for a complete kit of household goods that helps enhance their family's cleansing, sanitizing and disinfecting routine.
The Viraguard(R) product line is now available on the shelves of Canadian retailers including Loblaws and Lawtons Drugstores. Both retailers are carrying the full Viraguard(R) consumer product line which includes seven (7) SKUs:
Viraguard(R) Antiseptic Hand Spray (unscented) - 250ml/8oz;
Viraguard(R) Antiseptic Hand Spray (green apple) - 250ml/8oz;
Viraguard(R) Antiseptic Hand Spray (green apple) - 3 pack of 60ml/2oz;
Viraguard(R) Antiseptic Hand Wipes (lemon) - 20 count;
Viraguard(R) Surface Hospital Disinfectant Spray (unscented) - 250ml/8oz;
Viraguard(R) Surface Hospital Disinfectant Wipes (unscented) - 40 count; and
Viraguard(R) Family Health Kit (250ml/8oz antiseptic hand spray + 20 count antiseptic hand wipes + 250ml/8oz surface hospital disinfectant spray).
Initial orders from these retailers in excess of $500,000 CDN (approx. $450,000 USD) have already been shipped. Veridien is committed to growing its Viraguard(R) franchise and is currently working on a number of strategies that are intended to expand its presence in both the retail and institutional sectors of the Canadian and US markets.
The Company has initiated a family health program that is focused on raising public awareness about the benefits of integrating antiseptics and disinfectants as part of a consumer's cleansing routine, appropriately positioned as CLEAN HANDS + CLEAN HOUSE = FAMILY HEALTH. The Viraguard(R) products have been shown to be effective against a host of bacteria, viruses and other pathogens that have been known to compromise immunity and lead to debilitating diseases.
The Viraguard(R) infection control product line is available to health practitioners and industrial material managers through major distributors across the United States.
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995
Forward-looking statements in this press release (identifiable by such words as "believes", "expects", "planned") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.
About Veridien Corporation
For more information about Veridien Corporation and it investments in future technology, please visit: www.veridien.com and www.mycosol.com.
Source: Veridien Corporation
Veridien Corporation Reported Second Quarter 2006 Sales up 72% over Second Quarter 2005; Aggregate Sales Q3/Q4 2006 Projected to Be up 100% over Those Of Q3/Q4 2005
LARGO, Fla., Aug 15, 2006 (BUSINESS WIRE) -- Veridien Corporation (OTCBB:VRDE) reported a Second Quarter sales increase of 72% over Second Quarter 2005 sales ($265,054 vs. $153,339). Veridien is projecting aggregate third and fourth quarter sales (2006) of over $1.2 million, a level being double that of our third and fourth quarter 2005 sales. This 100% projected sales increase is based on purchase orders in hand of approximately $505,000, anticipated orders in late/final stages of negotiations and recurring orders from existing customers.
We have also been receiving significant inquiries about Veridien's patented Viraguard(R) Infection Control Products from companies who are involved in pandemic planning initiatives. We expect these corporate efforts to have a further favorable impact on our future sales activities.
About Veridien:
For more information about Veridien Corporation and its investments in future technology, please visit: http://www.veridien.com and http://www.mycosol.com.
Special Note: Forward-looking statements in this press release (identifiable by such words as "believes", "projecting", "anticipated", "expect") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes and other risks not identified herein. The Company disclaims any intent or obligation to update any forward looking statements.
SOURCE: Veridien Corporation
CONTACT: Veridien Corporation, Largo
Cheryl Ballou, 727-576-1600 x202
Copyright Business Wire 2006
-0-
KEYWORD: United States
North America
Florida
INDUSTRY KEYWORD: Seniors
Women
Youth
Health
AIDS
Alternative Medicine
Biotechnology
Cardiology
Fitness & Nutrition
Hospitals
Medical Devices
Mental Health
Pharmaceutical
Radiology
Consumer
Family
Gay & Lesbian
Men
SUBJECT CODE: Earnings
Search for Dun & Bradstreet reports on this company.
CEO Shelly Fenton of Veridien Corp. to Be a Featured Guest on 'Corporate Strategies Radio Show'
Friday June 9, 3:40 pm ET
LAS VEGAS--(BUSINESS WIRE)--June 9, 2006--Shelly Fenton, CEO of Veridien Corp. (OTCBB: VRDE - News), will be one of the featured companies on the "Corporate Strategies Radio Show," airing Sunday night from 9-10 p.m. EST. The Veridien Corp. produces a line of EPA-approved disinfectant products that are used primarily within the health care industry.
ADVERTISEMENT
Veridien Corp. has shown consistent growth in their marketing of their technologically advanced product line. They have projected that their product line will enter the mainstream consumer market in 2006 through standard supermarket presence instead of exclusive online sales. They maintain several development alliances and introduce new unique service products regularly.
The "Corporate Strategies" radio broadcast airs every Sunday evening on 400 different stations nationwide and is known for providing insider perspective on emerging and established companies.
Veridien Corporation Receives EPA Label Approval For Hepatitis A, B and C Kill Claims on Disinfectant Towelettes
ST. PETERSBURG, Fla., Oct 27, 2005 (BUSINESS WIRE) -- Veridien Corporation ( VRDE ):
-- The Patented Viraguard(R) Formula is the Only EPA Approved Disinfectant With Hepatitis A, B and C Label Claims That Is Also Drug Listed By the FDA As A Hand Antiseptic;
-- CDC estimates that 4.95 million Americans suffer from chronic hepatitis infections
Veridien Corporation ( VRDE ) announced today that the Viraguard(R) Hospital Hard Surface Disinfectant Towelettes have received stamped EPA approval for killing Hepatitis A, B and C viruses. These approvals now clearly distinguish the Viraguard(R) Disinfectant Towelettes as one of the premiere disinfecting wipes in the healthcare industry. Only Viraguard(R) Disinfectant Towelettes are authorized to make label claims about its effectiveness against all three Hepatitis viruses (A, B and C). The patented Viraguard(R) formula is the only EPA approved disinfectant with Hepatitis A, B and C label claims that is also drug listed by the FDA as a hand antiseptic.
According to the US Centers for Disease Control ("CDC"), the average rate of infections annually for hepatitis A, B and C is over 160,000 cases per year. As well, the CDC estimates that the number of Americans with chronic hepatitis infections exceeds 4.95 million people. ( www.cdc.gov/ncidod/diseases/hepatitis/resource/dz_burden02.htm)
In addition to the Hepatitis A, B and C kill claims, the Viraguard(R) Disinfectant Towelettes now carry all the viral and bacterial kill claims of the Viraguard(R) liquid disinfectants, including Methicillin-resistant Staphylococcus Aureus (MRSA), Vancomycin-resistant Enterococcus Faecalis (VRE), Herpes Simplex-type 1 and 2, Escheria coli (E.coli) strain 157, Mycobacterium bovis (BCG, TB surrogate), Pseudomonas aeruginosa, Streptococcus Pyogenes, Salmonella choleraesius, Staphylococcus aureus, Respiratory syncytial virus (RSV), Rotavirus (SA-11 Group A), Influenza Hong Kong type 1 and 2, HIV-1 (aids virus), Trichophyton mentagrophytes (athlete's foot fungus), Cytomegalovirus (CMV) and Adenovirus Type 2.
Paul Dunnigan, VP-Marketing Group, "This is outstanding news for our healthcare, industrial and retail clientele. With the new EPA approved label claims, Viraguard(R) Infection Control Products provide our customers with the full Hepatitis and anti-viral protection they need in surface disinfecting wipes as well as in liquid disinfectants. We offer them equal protection for hand sanitizing by using the same tested, safe and effective formula in our hand antiseptic products. In particular, Veridien's products are critical in helping to control orally transmitted pathogens (Hepatitis A) and blood-borne pathogens (Hepatitis C) that threaten food workers, emergency medical workers, clinicians and physicians worldwide. Veridien's strategic multi-national client and distributors regard the anti-viral kill claims as a distinct advantage to leverage large contracts in the health and safety industry."
Jeff Selph, Chief Scientific Officer of Veridien, said, "We live in a highly infected world. Numerous outbreaks of Hepatitis and other viruses are driving the need for products with superior kill claims. Healthcare and industrial professionals can depend on Viraguard(R) Infection Control Products to help minimize many of the risks."
Viraguard(R) Infection Control products are available to healthcare practitioners and industrial materials managers through major distributors across the United States. Viraguard(R) Products can also be purchased for use at home or at the office at www.buyveridien.com.
For more information about Veridien Corporation, A Life Sciences Company, its products and investments in future technology, go to:
http://www.veridien.com
and
http://www.mycosol.com
Special Note: Forward-looking statements in this press release (identifiable by such words as "believes","expects") are made pursuant to the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, market acceptance of, and demand for, the Company's products, manufacturing, development and distributor issues, product pricing, competition, funding availability, technological changes, and other risks not identified herein. The Company disclaims any intent or obligation to update any forward-looking statements.
SOURCE: Veridien Corporation
Veridien Corporation, Pinellas Park
Cheryl Ballou, 727-576-1600
cballou@veridien.com
Copyright Business Wire 2005
Veridien Corporation Announces Third Quarter 2003 Sales Revenue Estimated To Be Up By 225% Over Same Quarterly Period Last Year
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Oct. 17, 2003--Veridien Corporation (OTCBB:VRDE) announced today that third quarter 2003 sales revenue is estimated to be up 225% over sales revenue for the same quarterly period last year (2002).
Sheldon Fenton, CEO of Veridien, stated, "we are continuing to focus on expanding sales of our patented infection control products as we continue along our path to profitability. Recent developments with national contracts and distribution agreements with national and multi-national organizations bode well for our increased revenue and profitability goals."
For highlights of Veridien's accomplishments in 2003, please visit our website at http://www.veridien.com to review our 2003 press releases, including:
-- 09/15/03 Veridien Corporation Announces National Supply
Contract With American Red Cross
-- 08/14/03 Veridien Corporation's Revenue for First Six Month's
2003 Exceeds 2002 Full Year Revenue
-- 06/20/03 Veridien Corporation Meets Key Achievement Objective
-- 06/09/03 Veridien Corporation Named As Supplier of E.I.DuPont
de Nemours" New Line Of Antiseptic and Disinfectant Products
-- 05/14/03 Veridien Corporation Launches New Disinfectant Toilet
Seat Wipe Program
About Veridien
Veridien Corporation is a Health Care Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed PATENTED and UNIQUE PRODUCTS including SURFACE DISINFECTANTS, ANTISEPTIC HAND CLEANSERS, INSTRUMENT PRESOAK, AND SUN PROTECTANT PRODUCTS. The flagship product Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a skin friendly, patented, US- EPA and Health Canada registered, surface disinfectant. Viraguard(R) Antiseptic Hand Gel, Viraguard(R) Antiseptic Hand Spray, and Viraguard(R) Antiseptic Hand Wipes are US- FDA and Health Canada drug listed products utilizing Veridien's patented Virahol(R) formulation.
Look for Veridien at: http://www.vrde.com
And The SunSwipe Corporation L.L.C. at: http://www.sun-swipe.com
CONTACT:
Veridien Corporation, St. Petersburg
Investor Relations:
Cheryl Ballou, 727/576-1600
Veridien@GTE.net
Veridien Corporation Announces National Supply Contract With American Red Cross
ST. PETERSBURG, Fla.--(BUSINESS WIRE)--Sept. 15, 2003--Veridien Corporation (OTCBB:VRDE) today announced it has signed a supply contract with the American Red Cross. Veridien's patented Viraguard(R) Disinfectants and Wipes may be used by the Red Cross to meet regulatory requirements concerning the type of hard surface disinfectants used in Red Cross Biomedical Services facilities across America.
The products the American Red Cross has contracted for are:
Viraguard(R) Hospital Hard Surface Disinfectant Cleaner and Instrument Presoak
Viraguard(R) Antiseptic Hand Spray
Viraguard(R) Hospital Surface Disinfectant Towelettes
Viraguard(R) Antiseptic Hand Wipes
The Viraguard(R) products will be used for personal hand sanitation, disinfection of clinic surfaces and for maintenance of blood collection equipment. Viraguard(R) products will be available to Red Cross facilities effective September 15, 2003.
About Veridien
Veridien Corporation is a Health Care Company focusing on Infection Control and other Healthy Lifestyle products. Veridien has developed PATENTED and UNIQUE PRODUCTS including SURFACE DISINFECTANTS, ANTISEPTIC HAND CLEANSERS, INSTRUMENT PRESOAK, AND SUN PROTECTANT PRODUCTS. The flagship product Viraguard(R) Hospital Disinfectant/Cleaner and Instrument Presoak is a skin friendly, patented, U.S.-EPA and Health Canada registered, surface disinfectant. Viraguard(R) Hospital Surface Disinfectant Towelettes and Viraguard(R) Toilet Seat Wipes (Sit Secure(TM) program) are also U.S.-EPA registered. Viraguard(R) Antiseptic Hand Gel, Viraguard(R) Antiseptic Hand Spray and Viraguard(R) Antiseptic Hand Wipes are all U.S.-FDA and Health Canada drug listed products utilizing Veridien's patented Virahol(R) formulation.
Look for Veridien at http://www.veridien.com
"HEALTHY LIVING IS AN ADVENTURE - LET VERIDIEN GUIDE YOU"
CONTACT:
Veridien Corporation, St. Petersburg
Investor Relations:
Cheryl Ballou, 727/576-1600 ext. 202
cballou@veridien.com
Veridien Corporation Named as Supplier of E.I. du Pont de Nemours' New Line of Antiseptic and Disinfectant Products
ST. PETERSBURG, Fla., Jun 9, 2003 (BUSINESS WIRE) -- Veridien Corporation
(OTCBB: VRDE) was named by E.I. du Pont de Nemours and Company (NYSE:DD) in their
Daily News Press Release today as the exclusive supplier of the new line of
antiseptic and disinfectant products being launched by Dupont's Safety &
Protection group. The News Release specifically stated "DuPont antiseptic and
disinfectant products are manufactured exclusively for DuPont by Florida-based
Veridien Corporation."
The complete text of the News Release follows below and can also be found at
http://www.dupont.com under News and Media - Dupont Daily News for June 9, 2003:
"New Antiseptic and Disinfectant Products For Emergency Responders
June 09, 2003 --
To address the growing need to enhance the protection of emergency responders,
DuPont Safety & Protection is launching a new line of antiseptic and
disinfectant products that are effective against a wide range of human
pathogens.
The new line includes five products: DuPont(TM) Antiseptic Hand Wipes,
DuPont(TM) Antiseptic Hand Spray, DuPont(TM) Broad Spectrum Disinfectant
Solution, Spray and Wipes. First responders include firefighters, police,
emergency medical technicians, emergency medical services, HAZMAT response teams
and paramedics. This offering will also be extended to industrial users to
provide adequate disinfection protection for their front-line employees.
The DuPont(TM) Antiseptic Hand Wipes and DuPont(TM) Antiseptic Hand Spray
products are designed to protect first responders consistent with the new "Hand
Hygiene in Healthcare Settings" guidelines recently issued by the U.S. Centers
for Disease Control (CDC). These guidelines recommend healthcare facilities
across the nation increase use of alcohol-based hand rubs as an effective method
of reducing the risk of spreading germs. In addition, the CDC and World Health
Organization (WHO) have recommended detailed infection control methods,
including careful hand hygiene through frequent hand washing or use of
alcohol-based hand rubs in an effort to slow the spread of Sudden Acute
Respiratory Syndrome (SARS).
"Our products are designed to clean, disinfect and deodorize and are effective
against a wide range of pathogens that first responders face every day including
HIV, tuberculosis," said Tom Samples, DuPont Chemical Solutions Wellness
Solutions market leader. "They are available in convenient ready-to-use forms
including personal-use sizes and wipes for on-scene disinfection where they are
most needed to reduce the risk of infection."
These new DuPont personal protection products offer the broadest claims of any
exclusively alcohol-based, anti-microbial product on the market today and they
contain no toxic, irritating, or corrosive phenols, bleach, or quaternary
ammonium salts (quats) which have been implicated in creating anti-microbial
resistance.
The DuPont antiseptic products are formulated under Federal Drug Administration
(FDA) guidelines and the DuPont disinfectants are U.S. Environmental Protection
Agency (EPA) registered. DuPont antiseptic and disinfectant products are
manufactured exclusively for DuPont by Florida-based Veridien Corporation.
For more information, please visit our Web site at http://www.dupont.com or call
1-800-931-3456."
Media inquires are referred to Michelle Reardon at Dupont - Office: 302-992-4273
/ email: michelle.s.reardon@usa.dupont.com.
About Veridien
Veridien Corporation is a Health Care Products Company focusing on Infection
Control and other Healthy Lifestyle products. Veridien specializes in Patented
alcohol based Antiseptics and Disinfectants.
Veridien has developed PATENTED and UNIQUE PRODUCTS including SURFACE
DISINFECTANTS, ANTISEPTIC HAND CLEANSERS, INSTRUMENT PRESOAK, SUN PROTECTANT and
INSECT REPELLENT PRODUCTS. The flagship product Viraguard(R) Hospital
Disinfectant/Cleaner and Instrument Presoak is a skin friendly, patented, US-
EPA and Health Canada registered, surface disinfectant. Viraguard(R) Antiseptic
Hand Gel and Viraguard(R) Antimicrobial Towelettes are US- FDA and Health Canada
drug listed products utilizing Veridien's patented Virahol(R) formulation.
Look for Veridien at: http://www.vrde.com
And The SunSwipe Corporation L.L.C. at: http://www.sun-swipe.com
"HEALTHY LIVING IS AN ADVENTURE - LET VERIDIEN GUIDE YOU"
SOURCE: Veridien Corporation
CONTACT:
Veridien Corporation, St. Petersburg
Cheryl Ballou, 727/576-1600 Ext. 202
cballou@veridien.com
Recent PRs...........:
Thu, May 15 2:06pm EDT Veridien Corporation Projects Positive Quarterly EBITDA by Third Quarter 2003 (Source: Business Wire) (Full Story)
Thu, May 15 8:00am EDT Veridien Corporation Reports 21% Increase in First Quarter Operating Revenue; Positive Quarterly EBITDA Projected by Third Quarter 2003 (Source: Business Wire) (Full Story)
Wed, May 14 8:00am EDT Veridien Corporation Launches New Viraguard Disinfectant Toilet Seat Wipe Program (Source: Business Wire) (Full Story)
Thu, May 1 8:02am EDT Veridien Corporation Announces Agreement to Service Cruise Ship Industry (Source: Business Wire) (Full Story)
Mon, Mar 31 10:53am EST Veridien Corporation Announces Year-End 2002 Earnings Improvement; Expects 2003 Earnings Results to Be Best Since Inception; Positive Quarterly EBITDA Projected by Third Quarter (Source: Business Wire)
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48
|
Created
|
06/09/03
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |